NICE rejects Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second line mCRC
25 November 2011
Francesca Bruce
Please Login to read the full article.
25 November 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE scopes Sanofi/Regeneron's Zaltrap for colorectal cancer
- NICE: no evidence to approve Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second-line mCRC
- "Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
